Montana is quietly transforming into the epicenter of a radical experiment in American healthcare. By finalizing the regulatory framework for its “Right to Try” legislation, the Treasure State has effectively created the first legal pathway in the United States for biotech companies to market and sell experimental drugs to the general public outside of the traditional FDA-monitored clinical trial process.
This move represents a tectonic shift in the relationship between patients, pharmaceutical developers, and federal regulators. While the traditional pathway for experimental drug access is designed to protect consumers from the risks of unproven therapies, Montana’s new model prioritizes individual liberty, self-medication, and the acceleration of longevity science. As the first treatment clinics prepare to open their doors by the end of 2026, the nation is watching to see whether this "experimental hub" model will usher in a new era of medical freedom or serve as a cautionary tale of unchecked risk.
The New Regulatory Landscape: How the Model Works
Under the finalized rules established by the Montana Department of Health and Human Services, the process for bringing an experimental drug to market is remarkably streamlined. Any biotech firm with a drug that has passed preliminary testing—even in as few as ten healthy human subjects—can apply to a newly established, private Experimental Treatment Review Board (ETRB).
The application process requires a fee of $12,500, which funds the expert panel’s review. Once the ETRB grants approval, the company is authorized to set its own price for the treatment and sell it directly to patients through state-sanctioned experimental clinics.
Crucially, Montana’s law is not limited to the terminally ill. Access is open to any adult who provides informed consent and possesses the financial means to pay. This creates a dual-market scenario: one for patients with rare or neurodegenerative diseases seeking life-saving intervention, and another for the growing cohort of "longevity enthusiasts" interested in preventive, experimental therapies designed to extend healthspan.
A Chronology of the "Right to Try" Evolution
The journey to this moment began long before the current regulatory green light.
- 2015: Montana passes its initial Right to Try law, a measure focused on granting terminally ill patients access to experimental treatments.
- 2023: Recognizing a need for broader access, State Senator Ken Bogner introduces legislation to expand the law to include all patients, regardless of their diagnosis. This version shifts the focus toward preventive medicine.
- April 2025: A second, more granular bill is passed, explicitly outlining the operational guidelines for clinics offering FDA-unapproved drugs.
- July 2026: The Department of Health and Human Services officially finalizes the operational rules, clearing the path for the first independent review boards to begin evaluating applications.
- Late 2026: The first experimental treatment clinics are expected to become operational within the state.
This trajectory was significantly influenced by the Alliance for Longevity Initiatives (A4LI), a nonprofit dedicated to lifespan-extending policy, and tech entrepreneur Niklas Anzinger. Anzinger, previously involved in developing special economic zones in Honduras for medical innovation, pivoted to Montana, viewing it as a superior model due to its existing legal and regulatory infrastructure.
Supporting Data and the Expert Review Board
To ensure the process maintains a veneer of scientific rigor, the Montana ETRB—a private service managed by Montana Governance Services Inc.—has assembled a high-profile board. The five-member panel includes:
- Dr. James Burke: A Montana-licensed oncologist.
- Dr. Jessica Flanigan: A bioethicist and author of Pharmaceutical Freedom, an academic work advocating for the right to self-medicate.
- Dr. Felipe Sierra: A former director at the National Institutes of Health (NIH) and former chief scientific officer at the Hevolution Foundation.
- Dr. Matt Kaeberlein: A renowned scientist formerly of the Dog Aging Project, known for his work on rapamycin and aging.
- Dr. Jamie Justice: A gerontologist and executive director of the X Prize Healthspan competition.
The inclusion of such heavy hitters in the longevity community is a calculated effort to lend credibility to the program. Supporters argue that by centralizing these treatments in a transparent, monitored environment, the state can collect valuable data that might otherwise be lost if patients were to seek unproven "underground" cures abroad.
Official Responses and the FDA Conflict
The tension between state innovation and federal authority is palpable. While supporters believe they are filling a gap in the current system, the U.S. Food and Drug Administration (FDA) remains notably silent.
When questioned about the potential for biotech companies to face federal penalties for participating in the Montana program, an FDA spokesperson reiterated the agency’s policy of not commenting on state-level legislation. This ambiguity leaves companies in a state of high-stakes limbo.
"I wouldn’t bet on anything the FDA is saying today being applicable when the rubber hits the road," notes Chris Robertson, a specialist in health law at Boston University. Because federal law traditionally supersedes state law, there is a lingering fear that firms participating in the Montana program could see their standing with the FDA compromised, potentially endangering their ability to get products approved for the broader national market.
The Business of Hope vs. The Risk of Harm
The economic implications are equally complex. While companies like WinSanTor, which is developing treatments for peripheral neuropathy, argue they will sell their drugs "at cost" to help desperate patients, others may see the Montana market as an opportunity for high-margin revenue. With rare disease drugs frequently priced at over $200,000, the temptation to monetize early-stage research is significant.
However, the primary concern for critics remains patient safety. Harvard Medical School professor Aaron Kesselheim warns that the public perception of "safety" in early-stage trials is often dangerously misplaced.
"The idea that a drug has been proven safe because it’s been subject to a Phase I study is very, very wrong," Kesselheim argues. He maintains that the FDA’s existing "expanded access" pathway—which already approves over 99% of requests for terminally ill patients—is the gold standard. He views the Montana model not as a necessary innovation, but as a potential bypass of the safeguards intended to prevent widespread medical harm.
Implications for the Future of American Healthcare
Montana is betting that the desire for medical autonomy will outweigh the risks of decentralized regulation. By creating a legal sandbox for biotech innovation, the state has positioned itself as a lightning rod for the future of medicine.
If the Montana ETRB succeeds in fostering safe, data-rich clinical environments without significant adverse events, it could set a precedent for other states to follow, effectively decentralizing the pharmaceutical approval process. Conversely, if a high-profile medical tragedy occurs, the backlash could result in a federal crackdown that effectively ends the "Right to Try" movement in its tracks.
For now, the clinics are being outfitted, the medical directors are being hired, and two applications are already sitting on the board’s desk. In the coming months, the results of this experiment will begin to emerge, not in the pages of academic journals, but in the experiences of the patients who choose to step into the Montana clinics. Whether this represents the dawn of a new, empowered era of patient-driven medicine or a reckless disregard for established scientific protection remains the defining question of the decade.
